Some of the substantial names in AI have recently announced modern healthcare partnerships, funding, and implementations across a range of clinical operate cases. Here’s a sample.
Artificial intelligence improving cardiac MRI results
The company announced Tuesday that doctors at Amsterdam-based Royal Philips and Mayo Clinic will explore the operate of artificial intelligence to shorten intricate cardiac MRI scans and streamline radiology workflows.
Coronary heart disease is the leading cause of mortality worldwide, accounting for 13% of all global deaths, and access to high-quality MRI services is often restricted, Philips says.
Using a combination of the company’s magnet technology and Mayo Clinic’s proprietary artificial intelligence technologies, they hope to boost access and improve the patient experience during intricate cardiac MRI exams that can take over an hour to complete.
“From a patient’s perspective, MRI examinations can be stressful,” Ioannis Panagiotelis, business director for MRI at Philips, said in a statement.
“By applying artificial intelligence at every step of the cardiac MRI examination, we intend to expand access and significantly improve the patient experience, increase department efficiency and provide the detailed diagnostic information needed for optimal patient outcomes,” he said.
Modern funds for gynecological artificial intelligence
After signing an exclusive licensing agreement with Dana-Farber Cancer Institute of Boston last year to operate biomarkers to develop a non-invasive, basic, rapid and affordable method of ovarian cancer diagnosis, Aspira Women’s Health was among 23 winners of the Agency for Advanced Research Projects Health Sprint for Women’s Health in October for another non-invasive gynecological screening tool.
The company, a developer of bioanalytical diagnostics for gynecological diseases, announced this week that it has received a $2 million cash payment from ARPA-H to develop an artificial intelligence-based multi-marker blood test for the detection of endometriosiswhich may affect an estimated 5–10% of women and adolescents of reproductive age and up to 50% of infertile women.
Aspira proposes the operate of an algorithm that combines protein and microRNA biomarkers with patient data and uses technology that the company has pioneered in blood tests assessing the risk of ovarian cancer, it said in a statement.
“We are thrilled to announce that we have successfully reached our first milestone,” Nicole Sandford, CEO of Aspira, said in a statement.
Through the ARPA-H program, Aspira can receive up to $10 million in financing over two years with the intention of bringing the product to market after the agreement expires. Aspira is expected to reach the second milestone in the first quarter of 2025 and will be eligible to receive another cash payment of $1.5 million.
AWS has also provided funding to assist four 2024 ARPA-H Women’s Health award winners, including Aspira, the tech giant said Tuesday.
“Aspira Women’s Health is a leader in the application of machine learning to in vitro diagnostics, and we are excited to provide access to the comprehensive services and tools provided by AWS,” said Dr. Todd Pappas, the company’s vice president of research and development at AWS blog post.
“We believe this will expand our toolkit for developing and managing machine learning models and enable our data scientists to focus on maximizing the performance of our algorithms.”
More providers are adding genAI
While ambient AI does not necessarily improve an organization’s overall clinical performance, modern companies, health systems, specialty care providers, and private practices are extending generative AI tools to clinical users.
Michigan-based nonprofit Corewell Health said Thursday it has partnered with Abridge for enterprise-wide clinical documentation. Upon completion of the three-month pilot, Corewell will make the platform available to 4,000 physicians and advanced practice providers in 21 hospitals and more than 300 outpatient and post-operative facilities.
According to Abridge, 90% of Corewel physicians who used the AI documentation platform during the pilot reported a significant boost in the undivided attention they could give to patients and said they spent 48% less time documenting after work hours. Pilot testers of the healthcare system reduced “Pajama Time” from an average of 4.3 hours to 2.2 hours, the company said.
This ensures work-life balance Kristin Jacob, Corewell Health’s medical director of physician wellness and applications. In a statement, she said that thanks to the AI documentation, she gained time spent with patients and family.
“As a practicing physician, I have experienced first-hand the emotional and psychological effects of the burden of clinical documentation.”
To reduce nurses’ administrative burden and improve their experience, Brentwood, Tenn.-based MetaPhy Health, a provider of chronic care management services, is partnering with ActiumHealth to provide them with access to conversational AI-generating agents.
MetaPhy staff will have access to AI agents for phone calls, outreach and insights that can assist improve patient engagement “by providing consistent, empathetic and brand-aligned communications,” Adam Silverman, ActiumHealth’s chief medical officer, said in a statement Tuesday.
Behind schedule last month, healthcare data and technology provider Veradigm launched an AI-powered ambient writing tool powered by the AvodahMed platform that uses genAI to automate real-time patient-provider interactions and create structured medical notes in electronic records health.
Dr. Kent Wright, medical director and director of clinical integration at State of Franklin Healthcare Associates in Johnson City, Tennessee, said he has been waiting for the tool for a decade.
“This reduces the time needed for documentation and allows physicians to get back to the heart of medicine, which is providing high-quality care to patients,” he said.